Chimerix, Inc. (CMRX)
NASDAQ: CMRX · Real-Time Price · USD
8.46
-0.01 (-0.12%)
At close: Mar 14, 2025, 4:00 PM
8.45
-0.01 (-0.12%)
After-hours: Mar 14, 2025, 4:07 PM EST
Chimerix Revenue
Chimerix had revenue of $26.00K in the quarter ending September 30, 2024, with 136.36% growth. This brings the company's revenue in the last twelve months to $159.00K, down -85.98% year-over-year. In the year 2023, Chimerix had annual revenue of $324.00K, down -99.04%.
Revenue (ttm)
$159.00K
Revenue Growth
-85.98%
P/S Ratio
4,790.03
Revenue / Employee
$2,208
Employees
72
Market Cap
760.86M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 324.00K | -33.50M | -99.04% |
Dec 31, 2022 | 33.82M | 31.85M | 1,609.15% |
Dec 31, 2021 | 1.98M | -3.39M | -63.16% |
Dec 31, 2020 | 5.37M | -7.15M | -57.09% |
Dec 31, 2019 | 12.52M | 5.30M | 73.49% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
CMRX News
- 3 days ago - CHIMERIX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Chimerix, Inc. - CMRX - Business Wire
- 7 days ago - Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 9 days ago - SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CMRX and GLYC on Behalf of Shareholders - PRNewsWire
- 9 days ago - Jazz Pharma To Buy Chimerix For $935 Million, Strengthening Rare Cancer Pipeline - Benzinga
- 9 days ago - Jazz Pharmaceuticals to buy Chimerix for $935 million - Reuters
- 9 days ago - Jazz Pharmaceuticals to Acquire Chimerix, Further Diversifying Oncology Portfolio - GlobeNewsWire
- 22 days ago - Chimerix: Potential 'First' In Targeting Recurrent High-Grade Glioma Patients - Seeking Alpha
- 6 weeks ago - Chimerix to Present at JonesTrading Virtual Precision Medicine Symposium - GlobeNewsWire